The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer
Journal of Clinical Medicine · 17.09.2025 · 14 (18) · 6535
DOI: 10.3390/jcm14186535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 17.09.2025. Verfasst von Yakup Yalcin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, School of Medicine, Bursa Uludag University, Bursa 16110, Turkey. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objective: To evaluate the prognostic impact of lymphovascular space invasion (LVSI) on disease-free survival (DFS) and overall survival (OS) in patients with FIGO 2009 stage I endometrioid endometrial cancer with pathologically negative lymph node involvement.
Methods
This retrospective cohort study included 469 patients with FIGO 2009 stage I node-negative endometrioid endometrial carcinoma who underwent comprehensive surgical staging at a single tertiary center between January 1993 and April 2025. Demographic, clinicopathological, treatment, and follow-up data were collected. Survival outcomes were assessed using Kaplan–Meier analysis, and prognostic factors were identified via univariate and multivariate Cox regression models.
Results
LVSI was present in 17.7% of the cohort (n = 83). Patients with LVSI had significantly higher tumor grades, larger tumor size, and deeper myometrial invasion compared to LVSI-negative patients (p < 0.001). Recurrence was more frequent in the LVSI-positive group (14.5% vs. 6.5%, p = 0.026), with distant metastasis predominating (83.3%). The 5-year DFS was 86.4% in the LVSI-positive group versus 96.3% in the LVSI-negative group (p = 0.0020), while the 5-year OS was 72.1% vs. 91.2%, respectively (p = 0.0014). In multivariate analysis, LVSI was an independent prognostic factor for both recurrence (HR = 4.80, 95% CI: 1.62–14.21; p < 0.001) and overall mortality (HR = 3.33, 95% CI: 1.43–7.77; p = 0.012).
Conclusions
LVSI is a strong and independent predictor of adverse oncologic outcomes in early-stage, node-negative endometrioid endometrial cancer. Its presence is associated with significantly decreased DFS and OS, particularly due to an increased risk of distant recurrence. These findings support the incorporation of LVSI into contemporary risk stratification and adjuvant treatment algorithms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, School of Medicine, Bursa Uludag University, Bursa 16110, Turkey.
- Department of Obstetrics and Gynecology, Ali Osman Sonmez Oncology Hospital, Bursa 16110, Turkey.
ORCID-Profile: Yakup Yalcin, Serenat Yalcin, Merve Abay, Kemal Ozerkan
Zitieren
APA
Yalcin, Y., Kosan, B., Yalcin, S., Abay, M., & Ozerkan, K. (2025). The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer. Journal of Clinical Medicine, 14(18), 6535. https://doi.org/10.3390/jcm14186535
Vancouver
Yalcin Y, Kosan B, Yalcin S, Abay M, Ozerkan K. The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer. Journal of Clinical Medicine. 2025;14(18):6535. doi:10.3390/jcm14186535
BibTeX
@article{Yalcin2025,
author = {Yalcin, Yakup and Kosan, Bahadir and Yalcin, Serenat and Abay, Merve and Ozerkan, Kemal},
title = {The Impact of Lymphovascular Space Invasion on Recurrence and Survival in FIGO Stage I Node-Negative Endometrioid Endometrial Cancer},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {18},
pages = {6535},
doi = {10.3390/jcm14186535}
}
EUVIMED